Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4583 Monkeypox Concept

Trading 11-29 12:14:46 EST

1,309.09

+4.96

+0.38%

High1,311.69	Low1,302.56	Vol31.52M
Open1,304.18	D1 Closing1,304.13	Amplitude0.70%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O188.86M	T/O Rate--	Tradable Shares0.00
P/B3.221311	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1309.0925,"timestamp":1732900486449,"preClose":1304.133,"halted":0,"volume":31518717,"delay":0,"changeRate":0.003803,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":4.959473,"latestTime":"11-29 12:14:46 EST","open":1304.1781,"high":1311.6879,"low":1302.5588,"amount":188862166.568172,"amplitude":0.007,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732903200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.221311,"peRate":-308.341648,"turnoverRate":0.010458,"increases":6,"decrements":8,"flats":0,"marketCap":151117137868.5,"floatMarketCap":150378881191},"requestUrl":"/m/hq/s/BK4583/tweets","defaultTab":"tweets","newsList":[{"id":"2487734943","title":"OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2487734943","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487734943?lang=en_us&edition=fundamental","pubTime":"2024-11-28 23:29","pubTimestamp":1732807740,"startTime":"0","endTime":"0","summary":"Outlook TherapeuticsOTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010  to treat patients with wet age-related macular degeneration . The NORSE EIGHT study is the second of two adequate and well-controlled clinical studies evaluating ONS-5010 for the AMD indication.Per the data readout, the candidate failed to meet the pre-specified non-inferiority endpoint at week 8 outlined in the special protocol assessment with the FDA. ONS-5010 is an investigational ophthalmic formulation of bevacizumab, which is being developed to treat AMD and other retinal diseases. Shares of Outlook Therapeutics plunged 65.2% on Wednesday in response to the news.However, preliminary analysis of study data showed vision improvement, biological activity and a favorable safety profile for ONS-5010. Treatment with the candidate was also well-tolerated in the NORSE EIGHT study with overall ocular adverse event rates comparable to Lucentis.The sa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wYQLwM.yHAc_hHptSu_lhQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/701e76528de32ecfd8ed3df2f647e9a8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wYQLwM.yHAc_hHptSu_lhQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/701e76528de32ecfd8ed3df2f647e9a8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otlk-stock-falls-failure-meet-152900524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2250418816.HKD","ALLO","LU1803068979.SGD","LU2458330169.SGD","BK4530","LU0109394709.USD","LU1852331112.SGD","LU1894683348.USD","LU1988902786.USD","GFS","IE00BLSP4452.SGD","BK4599","BK4529","LU1571399168.USD","LU0979878070.USD","LU1057294990.SGD","LU1839511570.USD","LU0985481810.HKD","IE00BBT3K403.USD","LU0109392836.USD","LU0082616367.USD","IE0004445239.USD","BK4532","IE00BZ1G4Q59.USD","LU0889565916.HKD","PFE","LU0056508442.USD","LU0170899867.USD","OTLK","LU1585245621.USD","BK4554","BK4578","BK4568","GILD","BK4583","BK4141","LU0198837287.USD","LU0823434740.USD","BK4573","BK4585","LU0390134368.USD","BK4505","LU0321505868.SGD","LU1303367103.USD","IE00B19Z3581.USD","CRL","SG9999011175.SGD","LU0058720904.USD","IE00BMPRXN33.USD"],"gpt_icon":1},{"id":"2487345384","title":"APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2487345384","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487345384?lang=en_us&edition=fundamental","pubTime":"2024-11-28 23:13","pubTimestamp":1732806780,"startTime":"0","endTime":"0","summary":"Applied TherapeuticsAPLT announced that the FDA has issued a Complete Response Letter  for the new drug application  seeking approval for APLT’s lead candidate, govorestat, to treat classic galactosemia. The CRL stated that the FDA has reviewed the application and cannot approve the NDA in its current form due to deficiencies in the clinical study results submitted in support of the application.Applied Therapeutics isevaluating the FDA's feedback. It intends to promptly request a meeting to discuss the requirements for a potential NDA resubmission or appeal of the decision, and appropriate next steps. Shares of the company tanked 77.3% in the after-market hours, following the disappointing news.APLT’s govorestat  is a novel central nervous system penetrant ARI, which is currently being developed for three rare neurological diseases. The NDA for govorestat for the galactosemia indication was accepted by the FDA in late February under its Priority Review pathway.Year to date, shares of A","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T8SwUImUDIjgxL38j1nI4w--~B/aD00MTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T8SwUImUDIjgxL38j1nI4w--~B/aD00MTQ7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aplt-stock-plunges-77-fda-151300400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","LU0985481810.HKD","BK4505","SG9999001176.SGD","SG9999002224.SGD","SGXZ57979304.SGD","LU1057294990.SGD","LU0321505868.SGD","SG9999001176.USD","ALLO","LU1883839398.USD","BK4599","PFE","LU0321505439.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","APLT","GILD","IE00BSNM7G36.USD","LU0320765992.SGD","BK4581","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4007","CRL","LU0234570918.USD","LU1571399168.USD","LU0170899867.USD","BK4121","LU0225771236.USD","LU2087621335.USD","LU1066051498.USD","BK4534","IE00BBT3K403.USD","LU0234572021.USD","LU1023059063.AUD","SG9999013999.USD","BK4566","SG9999011175.SGD","BK4550","BK4532","LU1430594728.SGD","LU0456855351.SGD","BK4583","BK4588","IE00B19Z3581.USD","LU1894683264.USD","BK4139","BK4592"],"gpt_icon":1},{"id":"2486312186","title":"DEXIS Attends ADF, Showcases Award-Winning Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2486312186","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486312186?lang=en_us&edition=fundamental","pubTime":"2024-11-28 22:30","pubTimestamp":1732804200,"startTime":"0","endTime":"0","summary":"QUAKERTOWN, PA / ACCESSWIRE / November 28, 2024 / The latest AI-powered launches from DEXIS enhance diagnostics and patient care. At ADF, DEXIS showcased its innovative product line, including the new intraoral scanners and imaging products. The conference took place November 26-30 at the Palais des Congrès de Paris in Porte Maillot, France. The company's comprehensive range of award-winning solutions covers a complete digital diagnostic workflow, from intraoral scanning and implant planning to sensors, CBCT, and imaging software. With an expanded portfolio and ecosystem, DEXIS Solutions is designed to accelerate workflows, increase productivity, and improve the patient experience.\"Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us,\" said DEXIS President, Robert Befidi. \"We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jI1H34dFDeow8v0FaXfVgg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/d6e08b7678040919fa2590b2d1fb32bc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jI1H34dFDeow8v0FaXfVgg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/d6e08b7678040919fa2590b2d1fb32bc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dexis-attends-adf-showcases-award-143000845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVST","HKPD","BK4585","LU0648000940.SGD","H","LU0130103400.USD","BK4583","BK4082","LU1201861165.SGD","LU0130518102.USD","BK4142","LU0477156797.USD","EBS","BK4139"],"gpt_icon":0},{"id":"2486913313","title":"Why Quest Diagnostics Incorporated (DGX) Is One of the Most Undervalued Pot Stocks to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486913313","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486913313?lang=en_us&edition=fundamental","pubTime":"2024-11-28 18:30","pubTimestamp":1732789835,"startTime":"0","endTime":"0","summary":"We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Quest Diagnostics Incorporated  stands against other most undervalued pot stocks to buy according to analysts.A decade ago, the cannabis industry was in full swing as stock valuations exploded to record highs in states across the country legalizing pot use for medicinal and recreational purposes. Fast forward, valuations have crashed as harsh realities set in. While legalization on the state level has gathered pace in recent years, marijuana remaining illegal on the federal level is turning out to be one of the biggest stumbling blocks.The provision also prevents companies dealing in schedule one or two controlled substances from claiming tax credits. Consequently, reclassification would translate to about $3.5 billion being injected back into the sector, thus lowering the overall cost for capital and sparking a flurry o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NMUf7x6JVmUnzvbvIWeHtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/10bd4347eaf881880588241fb5202e9f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NMUf7x6JVmUnzvbvIWeHtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/10bd4347eaf881880588241fb5202e9f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-quest-diagnostics-incorporated-dgx-103035144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1854103824.USD","BK4588","BK4196","BK4585","DGX","BK4567","BK4583","LU1854104046.USD"],"gpt_icon":0},{"id":"2486389034","title":"BRIEF-Gilead Announces New England Journal Of Medicine Publication Of Purpose 2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2486389034","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486389034?lang=en_us&edition=fundamental","pubTime":"2024-11-28 07:23","pubTimestamp":1732749809,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Announces New England Journal Of Medicine Publication Of Purpose 2 ResultsNov 27 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION OF PUR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nTUA2S6FSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU2468319806.SGD","BK4566","LU0289739699.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU0889565916.HKD","BK4585","LU0320765992.SGD","LU1571399168.USD","LU0058720904.USD","BK4139","BK4588","GILD","LU2087621335.USD","LU1839511570.USD","LU0234570918.USD","LU1066051498.USD","IE00BSNM7G36.USD","LU1585245621.USD","IE00BKVL7J92.USD","BK4583","IE00B19Z3B42.SGD","BK4550","LU0109394709.USD","LU1066053197.SGD","BK4578","LU1430594728.SGD","BK4568","BK4532"],"gpt_icon":0},{"id":"2486753383","title":"Gilead announces PURPOSE 2 trial data published in NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2486753383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486753383?lang=en_us&edition=fundamental","pubTime":"2024-11-28 06:05","pubTimestamp":1732745127,"startTime":"0","endTime":"0","summary":"Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-announces-purpose-2-trial-data-published-in-nejm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-announces-purpose-2-trial-data-published-in-nejm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BSNM7G36.USD","IE00BKVL7J92.USD","BK4578","LU2087621335.USD","LU0234570918.USD","BK4568","LU0058720904.USD","BK4550","LU1430594728.SGD","GILD","BK4588","IE0002270589.USD","BK4566","BK4139","IE00BZ1G4Q59.USD","LU1066051498.USD","LU1839511570.USD","LU1571399168.USD","LU0320765992.SGD","LU1585245621.USD","LU2468319806.SGD","BK4583","BK4585","LU0109394709.USD","BK4532","LU1066053197.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2486388203","title":"Gilead Announces New England Journal of Medicine Publication of Purpose 2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2486388203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486388203?lang=en_us&edition=fundamental","pubTime":"2024-11-28 06:00","pubTimestamp":1732744800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nTUA2S6FSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","LU1066053197.SGD","BK4532","LU1585245621.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0109394709.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU1066051498.USD","BK4588","BK4139","LU0234570918.USD","LU2468319806.SGD","IE00BSNM7G36.USD","BK4578","LU1571399168.USD","LU1839511570.USD","BK4566","BK4583","LU2087621335.USD","BK4550","GILD","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4568"],"gpt_icon":0},{"id":"2486388217","title":"E-Home Household Service Restructures Capital to Boost Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2486388217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486388217?lang=en_us&edition=fundamental","pubTime":"2024-11-28 05:58","pubTimestamp":1732744730,"startTime":"0","endTime":"0","summary":"E-Home Household Service Holdings (EJH) has released an update. E-Home Household Service Holdings Limited has received shareholder approval for a s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/e-home-household-service-restructures-capital-to-boost-flexibility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/e-home-household-service-restructures-capital-to-boost-flexibility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EJH","HBCP","BK4192","BK4583","BK4539","BK4195","BK4211"],"gpt_icon":0},{"id":"2486871681","title":"ACAD Signs License Deal With Saniona for Rights to Neurology Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2486871681","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486871681?lang=en_us&edition=fundamental","pubTime":"2024-11-27 23:06","pubTimestamp":1732719960,"startTime":"0","endTime":"0","summary":"As its first indication, Acadia plans to study SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. The company is gearing up to initiate a mid-stage study of the candidate for the essential tremor indication in 2026.This strategic move aligns with ACAD’s longstanding commitment to delivering innovative therapies for patients with central nervous system disorders. Per the company, essential tremor has lacked innovative treatment options for decades, highlighting a significant unmet need. Leveraging Acadia’s extensive expertise in developing and commercializing advanced therapies for neurological disorders, the company aims to address this gap through its work with SAN711.Year to date, shares of Acadia have plunged 48.2% compared with the industry’s 7.8% decline.Revenues generated from the sales of Nuplazid are the majority contributor to Acadia’s top line. In the nine months ended Sept. 30, 2024, Nuplazid s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acad-signs-license-deal-saniona-150600406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","BK4130","LU1066053197.SGD","LU0690374615.EUR","LU1571399168.USD","LU0225771236.USD","BK4578","LU0545562505.USD","LU0321505439.SGD","BK4505","LU0306806265.USD","IE00BBT3K403.USD","IE00BFXG0V08.USD","BK4583","LU0456855351.SGD","LU2065171311.SGD","ALLO","PFE","BK4533","BK4528","LU0345774631.USD","BK4592","LU1066051498.USD","LU0823417653.USD","SG9999003800.SGD","IE00BYQQ9H92.USD","ACAD","BK4550","LU0170899867.USD","LU0234570918.USD","LU1228905540.USD","LU2065169927.USD","PWS","LU0823417737.USD","LU0058720904.USD","LU1691799644.USD","LU1221951129.SGD","LU2506952170.USD","IE00BZ1G4Q59.USD","ADP","LU1228905037.USD","LU1585245621.USD","IE000M9KFDE8.USD","LU0889565916.HKD","BK4007","LU2065171402.SGD","LU0122379950.USD","GILD","LU0225284248.USD","BK4566"],"gpt_icon":1},{"id":"2486884715","title":"Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884715","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884715?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:59","pubTimestamp":1732636740,"startTime":"0","endTime":"0","summary":"Shares of PSTX are up in pre-market trading on the acquisition news.Roche’s shares have lost 1.6% year to date against the industry’s growth of 6.4%.Per the terms, Roche will initiate a tender offer to acquire all of the outstanding shares of Poseida common stock for $9.00 per share in cash. PSTX’s stockholders would also receive a non-tradeable contingent value right  for up to an aggregate of $4.00 per share in cash, representing a total deal value of up to approximately $1.5 billion.The offer price of $9 represents a premium of approximately 215% to Poseida’s closing share price on Nov. 25, 2024.California-based Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf  CAR-T therapies across several therapeutic areas, including hematological malignancies, solid tumors and autoimmune disease, as well as manufacturing capabilities and technology platforms.Roche is currently looking to augment its pipeline after facing a few pipeline setbacks a couple of years ago","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-acquire-car-t-cell-155900367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","IE0002270589.USD","IE00BLSP4452.SGD","SG9999001176.SGD","LU1023059063.AUD","BK4532","BK4578","BK4592","LU1571399168.USD","SG9999002224.SGD","LU1894683348.USD","IE00BBT3K403.USD","BK4007","GILD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0225771236.USD","LU1066053197.SGD","IE00BLSP4239.USD","PFE","RHHBY","LU0985481810.HKD","IE000M9KFDE8.USD","BK4161","LU0289739699.SGD","LU0306806265.USD","BK4583","SG9999002232.USD","LU1057294990.SGD","LU0109394709.USD","BK4534","LU0234572021.USD","SG9999013999.USD","LU0889565916.HKD","CAR","PSTX","SG9999003800.SGD","LU0122379950.USD","BK4533","LU0170899867.USD","03165","CVR","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0456855351.SGD","LU2087621335.USD","BK4568","LU0058720904.USD","LU0321505439.SGD"],"gpt_icon":1},{"id":"2486071647","title":"Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486071647","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486071647?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"CHATHAM, N.J., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987334/28908/en/Tonix-Pharmaceuticals-to-Participate-in-the-NobleCon20-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","TNXP","BK4583","BK4135","BK4139"],"gpt_icon":0},{"id":"2486059060","title":"Gilead acquires investigational HIV vaccine from Spanish biotech Aelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2486059060","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486059060?lang=en_us&edition=fundamental","pubTime":"2024-11-26 03:11","pubTimestamp":1732561896,"startTime":"0","endTime":"0","summary":"MicroStockHub/E+ via Getty Images Gilead Sciences  has acquired assets related to a therapeutic HIV vaccine under development from Barcelona, Spain-based biotech Aelix Therapeutics. The vaccine uses the HTI immunogen which is \"designed to redirect the immune response toward the most vulnerable regions of HIV,\" according","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152883587/image_2152883587.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152883587/image_2152883587.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4331369-gilead-acquires-investigational-hiv-vaccine-spanish-biotech-aelix","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00B19Z3581.USD","LU1066053197.SGD","BK4532","LU1585245621.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0109394709.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU1066051498.USD","BK4588","BK4139","LU0234570918.USD","LU2468319806.SGD","IE00BSNM7G36.USD","BK4578","LU1571399168.USD","LU1839511570.USD","BK4566","BK4583","LU2087621335.USD","BK4550","GILD","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4568"],"gpt_icon":0},{"id":"2486443080","title":"Exploring Three High Growth Tech Stocks In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2486443080","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486443080?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:15","pubTimestamp":1732544125,"startTime":"0","endTime":"0","summary":"The United States market has shown robust performance, climbing by 2.2% over the past week with all sectors experiencing gains, and achieving a 32% increase over the last 12 months, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics using ribonucleic acid interference technology, with a market cap of $31.59 billion.Overview: Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical ne","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-141525525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU0109394709.USD","UBCP","LU1585245621.USD","LU1839511570.USD","ALNY","IE00B19Z3581.USD","BK4585","LU1571399168.USD","BK4568","LU1066051498.USD","IE00BSNM7G36.USD","BK4548","BK4583","BK4139","LU2087621335.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0234570918.USD","BK4566","BK4550","GLOB","IE00BKVL7J92.USD","BK4532","LU1430594728.SGD","BK4134","LU0058720904.USD","LU2468319806.SGD","IE00B0169N27.USD","BK4588","IE00BF5LJ272.USD","GILD","LU1066053197.SGD","LU0889565916.HKD","IE00BZ1G4Q59.USD","BK4211","LU2125910500.SGD","LU2045819591.USD","BK4578","IE0002270589.USD"],"gpt_icon":0},{"id":"2485298273","title":"3 ‘Buy’ stocks and 2 ‘Hold’ stocks according to Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485298273","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485298273?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:58","pubTimestamp":1732291099,"startTime":"0","endTime":"0","summary":"3D_generator Oppenheimer analysts provided technical analysis for five stocks, all rated “outperform.” This is “technical color” for stocks discussed in Oppenheimer’s research call by analysts. Buy Gilead Sciences  – Uptrend  This stock has a trend with “top-down headwinds from a relatively weak biotechnology  industry.” Corning  – Uptrend  The stock is attempting to break through its April 2021 peak. “It’s also notable the stock is still trading below its year-2000 high at $113,” analysts wrote. But its bullish trend and high-momentum “argues for a definitive breakout to a new cycle high over the coming weeks to months.” McGrath RentCorp  – Reversing higher The stock has been showing improvement since its late-October breakout above its 200-day average. However, its lower momentum score “leaves something to be desired,” analysts said. Hold Alcon  – Reversing lower The stock’s trend broke below its $89 resistance , and analysts see $82 as imminent support. RxSight  – Downtrend  This st","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520290362/image_520290362.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520290362/image_520290362.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322049-3-buy-stocks-and-2-hold-stocks-according-to-oppenheimer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK7094","BK4512","BK4534","BK4588","BK4566","LU1839511570.USD","IE00BFMHRM44.USD","BK4568","LU2087621335.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1804176565.USD","LU0109394709.USD","BK4127","LU2265009873.SGD","IE00B19Z3581.USD","BK4583","IE00BKVL7J92.USD","LU0058720904.USD","LU0348723411.USD","LU2468319806.SGD","LU1571399168.USD","BK4198","LU1066053197.SGD","XBI","IE00BSNM7G36.USD","LU1066051498.USD","LU0289739699.SGD","BK4532","IE0002270589.USD","LU0889565916.HKD","BK4578","ALC","BK4104","ALC.AU","LU1585245621.USD","BK4581","BK4148","MGRC","OPY","BK4550","BK4539","LU1430594728.SGD","BK4585","RXST","BK4139","IE00BZ1G4Q59.USD","GILD","LU0234570918.USD","GLW"],"gpt_icon":1},{"id":"2485260330","title":"Health care sector had the most stocks with 4-week low and RSI below 30 since spring","url":"https://stock-news.laohu8.com/highlight/detail?id=2485260330","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485260330?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:40","pubTimestamp":1732290008,"startTime":"0","endTime":"0","summary":"Two health care stocks that look “timely,” according to Krinsky:  Both Bristol Myers  – Up 38.12% in the last six months. Gilead Sciences  – Up 32.48% in the last six months.  Both have displayed bearish-to-bullish turnarounds in their charts over the last few quarters, Krinsky said. “The recent consolidations make both of them timely here, in our view.”","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251892842/image_1251892842.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251892842/image_1251892842.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4321978-health-care-sector-had-the-most-stocks-with-4-week-low-and-rsi-below-30-since-spring","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU1670710588.SGD","LU1839511570.USD","BK4578","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0225284248.USD","LU2242646821.SGD","GILD","LU1670710661.SGD","IE0009355771.USD","LU1989771016.USD","BK4559","LU0114720955.EUR","IE0002141913.USD","LU0061475181.USD","IE0002270589.USD","IE00B2B36J28.USD","LU1261432733.SGD","IHI","RSI","XBI","BK4150","LU0321505868.SGD","IE00BJT1NW94.SGD","BK4534","LU1718418525.SGD","LU1032466523.USD","LU0306806265.USD","LU2087621335.USD","BMY","LU2133065610.SGD","BK4585","IE00BFTCPJ56.SGD","LU2125154778.USD","LU1323610961.USD","BK4139","LU1670711040.USD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4550","XLV","LU0058720904.USD","LU0320765992.SGD","BK4007","LU0234570918.USD","LU1291159041.SGD","BK4583","IE00B19Z3581.USD","LU2125154935.USD"],"gpt_icon":0},{"id":"2485265037","title":"Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265037","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265037?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:02","pubTimestamp":1732284138,"startTime":"0","endTime":"0","summary":"Viatris  has been fined 1.5 million UK pounds  by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.The regulator said Viatris breached restrictions imposed on it during an investigation by \"implementing changes to key members of its UK management team\" without consent and failing to notify authorities of the breach.Viatris did not immediately reply to MT Newswires' request for comment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4583","BK4007","BK4585","BK4588","VTRS","LU1839511570.USD","LU2087621335.USD"],"gpt_icon":0},{"id":"2485728252","title":"BUZZ-U.S. STOCKS ON THE MOVE-Gold miners Ross Stores, NetApp","url":"https://stock-news.laohu8.com/highlight/detail?id=2485728252","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485728252?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:46","pubTimestamp":1732279575,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Gold miners Ross Stores, NetAppEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROST","LU0865486749.SGD","LU0128525689.USD","NEM","INTU","BK4502","SGXZ99366536.SGD","LU0654597011.USD","LU0633140727.USD","LU0543330483.HKD","NTAP","V","RUN","LU1037948541.HKD","LU0724618789.USD","BK4583","LU2023251221.USD","LU0708995583.HKD","LU2498475776.HKD","BK4559","BK4587","BK4504","LU0880133367.SGD","LU1769817096.USD","SG9999018857.SGD","LU0444973449.USD","89618","IE00B19Z8X17.USD","LU1815336760.USD","LU2257852520.SGD","LU0545562505.USD","LU1023059493.AUD","LU0823414551.USD","LU1883866441.USD","LU2361044865.SGD","SG9999001424.SGD","VTRS","BK4007","IE00BQXX3C00.GBP","LU2210149790.SGD","BK4558","LU1852331112.SGD","LU0957791311.USD"],"gpt_icon":1},{"id":"2485225988","title":"Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program","url":"https://stock-news.laohu8.com/highlight/detail?id=2485225988","media":"TipRanks","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485225988?lang=en_us&edition=fundamental","pubTime":"2024-11-22 19:35","pubTimestamp":1732275353,"startTime":"0","endTime":"0","summary":"Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Hookipa Pharma price target lowered to $48 from $50 at RBC Capital. Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes. Closing Bell Movers: Applied Materials down 6% after earnings, guidance. JMP Securities healthcare analysts hold an analyst/industry conference call","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hookipa-pharma-announces-workforce-reduction-113553263.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hookipa-pharma-announces-workforce-reduction-113553263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU1066053197.SGD","BK4532","LU1585245621.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0109394709.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU1066051498.USD","BK4588","BK4139","LU0234570918.USD","LU2468319806.SGD","IE00BSNM7G36.USD","BK4578","LU1571399168.USD","LU1839511570.USD","BK4566","BK4583","BK4505","LU2087621335.USD","BK4550","GILD","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4568","HOOK"],"gpt_icon":0},{"id":"2485700255","title":"Viatris fined £1.5M for failure to comply with CMA order","url":"https://stock-news.laohu8.com/highlight/detail?id=2485700255","media":"seekingalpha","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485700255?lang=en_us&edition=fundamental","pubTime":"2024-11-22 19:26","pubTimestamp":1732274818,"startTime":"0","endTime":"0","summary":"Frank Brennan/iStock via Getty Images  Generic drugmaker Viatris  has been 1.5M by the U.K.'s Competition and Markets Authority  for failing to comply with compulsory restrictions imposed during the regulator’s review of its deal with Theramex. In Oct. 2023, Viatris  agreed to divest its rights to women’s health products, Duphaston and Femoston, to Theramex. Duphaston and Femoston, which comprise progesterone and estrogen receptor agonists, are prescribed as hormone replacement therapy  to help relieve menopause symptoms. Following a Phase 1 probe, in April 2024, the CMA said the deal would likely hurt competition in the HRT market. The antitrust regulator imposed an ‘Initial Enforcement Order’ which sought to prevent any action which could prejudice its inquiry or any potential remedies that the CMA might impose. The regulator said Viatris  breached these restrictions by implementing changes to key members of its UK management team without the CMA’s consent, and then failed to notify ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142910891/image_2142910891.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142910891/image_2142910891.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4320334-viatris-fined-15m-for-failure-to-comply-with-cma-order","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["CMA","BK4589","LU2087621335.USD","BK4007","LU1839511570.USD","HRT","BK4207","BK4211","VTRS","BK4583","BK4130","BK4588","BK4585"],"gpt_icon":0},{"id":"2485255227","title":"BUZZ-Viatris falls after $1.9 mln fine by UK watchdog","url":"https://stock-news.laohu8.com/highlight/detail?id=2485255227","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485255227?lang=en_us&edition=fundamental","pubTime":"2024-11-22 19:24","pubTimestamp":1732274648,"startTime":"0","endTime":"0","summary":"BUZZ-Viatris falls after $1.9 mln fine by UK watchdog** Shares of drugmaker Viatris Inc VTRS.O down 2.6% at $12.91 premarket** Britain's Competition and Markets Authority  fines VTRS 1.5 mln pounds  for breaching legally binding restrictions during its probe into Theramex's purchase of two Viatris product ranges** CMA says VTRS made unapproved changes to key UK staff  without the regulator's consent, and failed to report the breach** VTRS did not immediately respond to a Reuters request for comment** As of last close, stock has risen 22.4% YTD vs. 6.5% increase in the S&P 500 pharmaceuticals sub index .SPLRCCARD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT0RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4583","VTRS","LU2087621335.USD","BK4585","BK4007","BK4588"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.031},{"period":"3month","weight":0.0725},{"period":"6month","weight":0.1355},{"period":"1year","weight":0.3163},{"period":"ytd","weight":0.2599}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4583","nameEN":"BK4583"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monkeypox Concept,BK4583,Monkeypox Concept股票,Monkeypox Concept股票老虎,Monkeypox Concept股票老虎国际,Monkeypox Concept行情,Monkeypox Concept股票行情,Monkeypox Concept股价,Monkeypox Concept股市,Monkeypox Concept股票价格,Monkeypox Concept股票交易,Monkeypox Concept股票购买,Monkeypox Concept股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction